Abstract:AIM: To explore the effect of atorvastatin on the retinal expression of peroxisome proliferator-activated receptors (PPARs) and its anti-apoptotic and pro-survival effects against excitotoxic retinal injury. METHODS: An in-silico study was conducted to determine the affinity of statins towards PPARs and the one with maximum affinity was chosen for further studies. Rats were intravitreally administered with N-methyl-D-aspartate (NMDA), with or without statin pre-treatment, at doses ranging from 0.1 to 100 µmol/L. Retinal Bcl-2-associated X protein (BAX), Bcl2, caspase-3, RNA-binding protein with multiple splicing (RBPMS) expressions were determined to assess pro-apoptotic and pro-survival effects. To further corroborate the findings, haematoxylin & eosin (H&E)-stained retinal sections were examined to evaluate retinal morphology. Furthermore, the effect of atorvastatin on retinal expression of PPARs in the presence and absence of excitotoxic injury was determined. RESULTS: Among the six statins, atorvastatin demonstrated the highest affinity towards PPARα and PPARγ receptors. Among five doses, atorvastatin at a dose of 20 µmol/L dose showed the most significant reduction in BAX/Bcl-2 and cleaved/procaspase-3 ratios (P<0.0001). RBPMS expression and morphological studies confirmed the most prominent protective effect of atorvastatin at 20 µmol/L dose. Additionally, this optimum dose of atorvastatin inhibited NMDA-induced changes in retinal PPARα and PPARγ expression. CONCLUSION: Atorvastatin prevents NMDA-induced retinal cell apoptosis and promotes retinal ganglion cell survival in rats. This effect of atorvastatin is associated with inhibition of NMDA-induced changes in retinal PPARα and PPARγ expression. Importantly, this study not only highlights the role of PPARs in the neuroprotective effect of atorvastatin but also demonstrates contrasting effects of excitotoxic injury on retinal PPAR expression under these experimental conditions.